Clinical trials: Liver Transplant Rejection
Acute Rejection of Liver Transplant, Effects of Immunosuppressant Therapy
SRL (Sirolimus) Withdrawal
The significance of this clinical trial lies in its potential to increase the success of immunosuppression (IS) therapy withdrawal in liver transplant (LT) recipients, thus decreasing the negative impact of IS on their long-term…
- Trial name
- SRL (NCT02062944)
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Northwestern University
Intestinal Microbiota, Complication of Transplanted Liver
Human Microbiota and Liver Transplant
The microbiota represents the collections of microbial communities that colonize a host. In health, the microbiota protects against pathogens and maturation of the immune system.
- Conditions
- Intestinal Microbiota, Complication of Transplanted Liver, Acute Rejection of Liver Transplant, Infection
- Trial name
- NCT02223468
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hospital Vall d'Hebron
Autoimmune Liver Disease, Autoimmune Hepatitis
TruGraf Liver Gene Expression Serial Test
This is an Investigator Initiated, single center, non-randomized, single arm study utilizing TruGraf liver gene expression serial testing in patients with autoimmune liver diseases (AIH, PSC, PBC) monthly for the first 6 months…
- Conditions
- Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
- Trial name
- NCT06061341
- Testing
- TruGraf®
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Washington University School of Medicine
Liver Transplant Rejection, Immune System Suppression
Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients
Prograf and Envarsus are two different formulations of Tacrolimus which is used as an immunosuppressant in liver transplant (LT) patients.
- Trial name
- NCT05655273
- Testing
- Prograf, Envarsus
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Liver Disease
Role of Tissue C4d in Differentiation Between Acut e Rejection and HCV Recurrence After Liver Transplantation
Assessment of the role of tissue C4d complement fragments in liver biopsy as a new marker for differentiating between acute rejection and Hepatitis C (HCV) recurrence in recipients post living donor liver transplantation (LDLT)…
- Trial name
- NCT02209675
- Testing
- liver biopsy
- Where
- Egypt
- Volunteers
- 25 people
- Sponsor
- Ain Shams University
Liver Diseases, Liver Dysfunction
Global Utilization And Registry Database for Improved preservAtion of doNor Livers
The objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor liver that were preserved and transported within the LIVERguard system, as well as…
- Conditions
- Liver Diseases, Liver Dysfunction, Liver Transplant Disorder, Liver Transplant Rejection
- Trial name
- NCT05082077
- Testing
- LIVERguard
- Where
- 15 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Paragonix Technologies
Hepatic Transplantation, Rejection; Transplant, Liver
Tissue Analysis of Liver Grafts as a Predictor of Transplant Outcome.
Despite the good clinical results in terms of outcome with the application of HOPE prior to liver transplantation, very little is still known about the phenotypic and molecular changes that occur during perfusion/preservation…
- Trial name
- NCT06717542
- Testing
- histochemical and immunohistochemical analysis, RT-PCR
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Liver Diseases, Alcoholic, Alcohol-Related Disorders
Cohort/Ethics Study of Patients With Severe Alcoholic Hepatitis Undergoing Early Liver Transplantation
The purpose of this study is to develop a clinical understanding of early liver transplantation (ELT) for patients with severe alcoholic hepatitis (SAH) and identify the public's opinion regarding this practice.
- Conditions
- Liver Diseases, Alcoholic, Alcohol-Related Disorders, Transplant; Failure, Liver, Transplant; Complication, Rejection
- Trial name
- NCT04234139
- Testing
- liver transplant
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Johns Hopkins University
Liver Transplant Rejection, Kidney Transplant; Complications
VOCs in Kidney and Liver Transplants
Kidney and liver trasplants represent very challenging lifesaving and effective surgical procedures for patients with end-stage kidney and/or liver disease.
- Trial name
- NCT04514666
- Testing
- Breath analysis
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Societa Italiana di Chirurgia ColoRettale
Liver Transplantation, Graft Versus Host Disease
The Effect of Human Leukocyte Antigen Macthing on Guiding Tacrolimus Regimen After Liver Transplantation
The aim of this research is to design a randomized controlled clinical study, which is based on HLA matching rate to guide tacrolimus regimen.
- Conditions
- Liver Transplantation, Graft Versus Host Disease, Graft Rejection, Drug-Related Side Effects and Adverse Reactions
- Trial name
- NCT03147157
- Testing
- tacrolimus regimen guided by HLA matching rate
- Volunteers
- 120 people
- Sponsor
- The First Hospital of Jilin University
Liver Transplantation, Thymoglobulin
rATG Induction and Tacrolimus Monotherapy in Pediatric Liver Transplantation
This open-label clinical trial will evaluate the pharmacodynamics, pharmacogenomics and early efficacy and safety of steroid-free Tacrolimus (TAC) monotherapy and its minimization after induction with rabbit, anti-human thymocyte…
- Conditions
- Liver Transplantation, Thymoglobulin, Rejection
- Trial name
- NCT01207141
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Pittsburgh
Liver Failure, Liver Failure, Acute
Use of N-Acetylcysteine During Liver Procurement
Randomized prospective study on the impact on the post-LT outcome by the infusion of N-acetylcysteine (NAC) during the liver procurement procedure, as an anti-oxidant agent to reduce the ischemia-reperfusion damage of organs for…
- Conditions
- Liver Failure, Liver Failure, Acute, Liver Diseases, Carcinoma, Hepatocellular
- Trial name
- NCT01394497
- Testing
- N-acetylcystein
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- Azienda Ospedaliera di Padova
Liver Transplant, Hepatocellular Carcinoma Recurrent
Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
The prognosis of liver transplanted (LT) patients with recurrence of hepatocellular carcinoma (HCC), especially those with progression after locoregional treatment or advanced HCC, remains poor.
- Conditions
- Liver Transplant, Hepatocellular Carcinoma Recurrent, Systemic Treatment
- Trial name
- IMMUNO-TH (NCT06254248)
- Testing
- Systemic therapy
- Where
- 10 sites in France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Cellular Graft Rejection, New Onset Diabetes After Transplant
Budesonide for Liver Transplant Immune Suppression
This is a pilot study that investigates the efficacy and safety of budesonide as an immune suppressing agent for liver transplant recipients in the early post-transplant period.
- Trial name
- NCT03304626
- Testing
- Budesonide 3Mg Capsule, Standard of Care Prednisone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Cincinnati
Liver Transplant Rejection
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension
This was a multicenter, open-label, active-controlled study to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of two CFZ533 maintenance doses in de novo liver transplant recipients.
- Trial name
- CONTRAIL I (NCT03781414)
- Testing
- CFZ533, Tacrolimus - MMF - corticosteroids
- Where
- 29 sites in United States, Argentina and 8 more
- Volunteers
- 129 people
- Sponsor
- Novartis Pharmaceuticals
Liver Transplantation
Gene Expression in Liver Allograft Rejection and Recurrent Hepatitis C
Acute cellular rejection is relatively common after liver transplantation, typically does not affect graft survival, and is not associated with the development of chronic rejection.
- Trial name
- NCT01428700
- Volunteers
- 275 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Hepatitis C, Chronic
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
In order to prevent organ rejection, patients receiving liver transplants currently require life-long treatment with immune system-suppressing medications to prevent the rejection of the transplanted liver.
- Conditions
- Hepatitis C, Hepatitis C, Chronic, Nonimmune Nonviral Causes of Liver Failure
- Trial name
- A-WISH (NCT00135694)
- Testing
- calcineurin inhibitor-based immunosuppression, liver transplant, corticosteroids
- Where
- 8 sites in United States
- Volunteers
- 275 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Transplant Rejection
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.
Our study aimed at studying the impact of gene polymorphism of NFKBIA and PTPN22 genes on rejection episodes in liver transplant Egyptian recipients. Also assess patients' factors associated with graft rejection.
- Trial name
- NCT06060808
- Testing
- gene polymorphism
- Where
- Egypt
- Volunteers
- 105 people
- Sponsor
- Helwan University
Heart Transplantation, Kidney Transplantation
A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time
The purpose of this study is to compare how the body absorbs and processes two different formulations of the anti-rejection medication tacrolimus (Advagraf® or Prograf®) in children receiving an organ transplant, and how safe and…
- Conditions
- Heart Transplantation, Kidney Transplantation, Liver Transplantation
- Trial name
- NCT01614665
- Testing
- Tacrolimus, Tacrolimus prolonged release
- Where
- 10 sites in Czechia, France and 3 more
- Volunteers
- 44 people
- Sponsor
- Astellas Pharma Europe Ltd.
Liver Transplant Rejection, Liver Transplant; Complications
Safety of DNP007 in Healthy Subjects
This clinical trial evaluated the safety, tolerability, pharmacokinetic properties, and immunogenicity of DNP007 when administered as a single dose.
- Conditions
- Liver Transplant Rejection, Liver Transplant; Complications, Steatohepatitis, Nonalcoholic
- Trial name
- NCT06400771
- Testing
- DNP007
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital